Featured Story

Charles River Acquires Cellero

Cellero logo

We are pleased to announce the acquisition of Cellero (formerly Key Biologics and Astarte Biologics), a premier provider of cellular products for cell therapy developers and manufacturers worldwide.

Cellero will complement Charles River’s recent acquisition of HemaCare by enhancing the supply of critical biomaterials, including a wide range of human-derived primary cell types to support the discovery, development, and manufacture of cell therapies.

The combination of Cellero with HemaCare will enhance Charles River’s unique, comprehensive solutions for the high-growth cell therapy market, strengthening its ability to help accelerate clients’ critical programs from basic research and proof-of-concept to regulatory approval and commercialization. It will also expand Charles River’s provision of high-quality, human-derived biomaterials and related services with Cellero’s unique product portfolio and donor sites in both the eastern and western United States.